Labeling a target as “undruggable” may reflect the limitations of the screening libraries employed rather than an inherent inability to modulate the biology.
Expanding accessible molecular diversity by three orders of magnitude fundamentally alters the probability landscape, enabling the discovery of binders that were previously beyond statistical reach.
That is the core argument for mRNA display, and how it contributes to IRBM’s therapeutic peptides discovery platform:
fully cell-free, enables the exploration of ultra-large libraries that are inaccessible to cell-based technologies
screening up to 10¹³ unique peptide variants with tailored selection conditions tunable at every round
macrocyclic architectures generated via Cys-Cys cyclization directly from the primary screen
NGS-based enrichment monitoring at each cycle
Standard campaigns run 6 to 10 selection rounds with negative deselection, delivering high-specificity binders in the nanomolar to picomolar range.
Alongside IRBM’s established phage display technologies, mRNA display provides partners with a complementary discovery platform, maximizing the identification of therapeutic peptide leads.
If your target has resisted conventional screening, this is where the conversation starts.
Find out more